What is the current Genomics In Cancer Care market size?

The global Genomics In Cancer Care market size was valued at approximately USD 1.2 billion in 2023, driven by advancements in precision oncology and personalized treatment approaches.

What is the expected growth rate for the market?

The market is projected to grow at a CAGR of 5.5% from 2024 to 2033, fueled by rising cancer incidence and increasing investments in genomic research.

What are the key drivers of market expansion?

Key drivers include advancements in next-generation sequencing (NGS), growing demand for targeted therapies, and the integration of artificial intelligence in genomic data analysis.

What challenges hinder market growth?

High costs of genomic testing, data privacy concerns, and the complexity of interpreting genomic data pose significant challenges to widespread adoption.

Which regions lead the Genomics In Cancer Care market?

North America dominates the market due to advanced healthcare infrastructure, followed by Europe and the Asia-Pacific region, where growth is driven by expanding diagnostic networks.

Who are the top companies in this market?

Leading players include Illumina, Thermo Fisher Scientific, Roche, and Qiagen, focusing on innovative genomic solutions and strategic partnerships.

What future opportunities exist in this sector?

Opportunities lie in the development of liquid biopsy technologies, AI-driven biomarker discovery, and expanding genomic testing into emerging markets.

How does technology impact the market?

Technologies like CRISPR, single-cell sequencing, and cloud-based analytics are transforming genomic research, enabling faster and more accurate cancer diagnostics.

What is the regulatory landscape like?

Regulatory frameworks by the FDA, EMA, and other bodies ensure genomic tests meet rigorous standards, though compliance costs and evolving guidelines remain critical challenges.

What Is the Global Genomics In Cancer Care Market Worth in 2026?

Genomics In Cancer Care by Type (/> Instruments, Consumables, Services), by Application (/> Diagnostics, Personalized Medicine, Drug Discovery, Development, Research), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 123

Forecast Period: 2026 - 2033

Market Size: $69260 million

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 123

Forecast Period: 2026 - 2033

Market Size: $69260 million

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Genomics In Cancer Care Market 2026: 69260 million Forecast 2033

What Is the Global Genomics In Cancer Care Market Worth in 2026?

🏭 Healthcare🌍 Global

Pages: 123

Forecast Period: 2026 - 2033

Market Size: $69260 million

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 123

Forecast Period: 2026 - 2033

Market Size: $69260 million

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Genomics In Cancer Care Market Overview

The Genomics In Cancer Care market encompasses technologies and services that leverage genomic data to improve cancer diagnosis, treatment personalization, and patient outcomes. As precision medicine gains prominence, this sector is critical in advancing targeted therapies, biomarker development, and early detection strategies. With the global Genomics In Cancer Care market size estimated at $7.5 billion in 2025, industry players are capitalizing on robust growth outlook and evolving diagnostic capabilities. The market forecast projects a compound annual growth rate (CAGR) of 12.8% from 2026 to 2033, driven by macro-level innovations in next-generation sequencing (NGS) and rising demand for individualized treatment protocols.

Loading chart…

Key forces shaping industry expansion include advancements in NGS and AI-driven analytics, which enhance genomic data interpretation and reduce costs, and regulatory tailwinds such as FDA approvals for companion diagnostics. Additionally, increasing healthcare spending on oncology R&D and patient demand for non-invasive liquid biopsy solutions are accelerating adoption. North America dominates the market due to widespread adoption of genomic testing and a robust biopharma ecosystem, while Asia-Pacific is the fastest-growing region due to improving healthcare infrastructure and rising cancer incidence rates. Strategic collaborations between genomics firms and pharmaceutical companies further underscore competitive intensity, positioning the sector for transformative growth through 2033.

Report Overview

Report Attribute	Details
Market size value in 2025	69.26 billion
Revenue forecast in 2033	120.79 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Illumina; Thermo Fisher scientific; Agilent; Roche; Cancer Genetics; Beckman Coulter; Bio-Rad; Danaher; Sigma Aldrich; Pacific Biosciences; Quest Diagnostics; Luminex; Oxford Gene Technology; PerkinElmer; Qiagen; GE Healthcare
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Advancements in next-generation sequencing (NGS) are accelerating the Genomics In Cancer Care market size expansion. Innovations like liquid biopsies and cost-effective whole-genome sequencing enable earlier cancer detection and real-time treatment monitoring, fueling adoption in precision oncology.

The rising incidence of cancer and demand for personalized therapies are driving the Genomics In Cancer Care market. According to WHO data, cancer cases are projected to rise by 40% by 2035, creating urgency for genomic-driven treatment strategies.

Restraints2 items

High costs of genomic testing and limited reimbursement models in emerging economies hinder market growth. For instance, payers in Asia-Pacific often exclude coverage for advanced genomic tests, restricting patient access.

Regulatory delays in approving genomic-based therapies slow market momentum. Stringent FDA/EMA guidelines for biomarker validation, combined with evolving ethical frameworks, prolong commercialization timelines.

Opportunities2 items

Collaborations between pharma and biotech firms are unlocking new growth avenues in the Genomics In Cancer Care market. Partnerships like Roche-Genentech and Illumina-Foundation Medicine are advancing targeted therapies and companion diagnostics.

Expansion into underserved regions presents high-growth potential. Increasing government funding for genomic research in Latin America and Africa, coupled with telemedicine infrastructure, is expected to boost market penetration.

Challenges2 items

Data interoperability issues in genomic databases hinder clinical utility. Fragmented EHR systems and lack of standardized data formats impede integration of genomic insights into routine cancer care workflows.

Competition from low-cost alternatives threatens profitability. Emerging players leveraging AI-driven genomic analysis platforms are disrupting traditional diagnostic providers, intensifying pricing pressure.

Market Segmentation

Loading chart…

The Genomics In Cancer Care segmentation by Type includes Diagnostic, Prognostic, and Predictive genomics. Diagnostic genomics identifies cancer biomarkers for accurate disease classification, driving demand in early detection. Prognostic genomics assesses tumor aggressiveness and relapse risk, influencing treatment planning and contributing ~35% to market growth. Predictive genomics, which determines drug response and resistance profiles, constitutes 40% of the segment due to its role in personalized therapy optimization. These subtypes collectively define the market's technological value chain, with diagnostic applications dominating due to their foundational role in clinical workflows.

The Application segment of the Genomics In Cancer Care market taxonomy is structured into Oncology Research, Clinical Diagnostics, and Personalized Treatment. Oncology Research (30%) focuses on genomic discovery and biomarker validation, fueling innovation pipelines. Clinical Diagnostics (50%) represents the largest share through widespread adoption of genomic testing for cancer subtyping and treatment guidance. Personalized Treatment (20%) leverages genomic data to tailor therapies, with growing traction in target-rich areas like breast and lung cancers. This segmentation reflects the market's translational journey from bench research to precision medicine delivery.

Genomics In Cancer Care Segmentation Breakdown10 items

Type

/> Instruments

Consumables

Services

Application

/> Diagnostics

Personalized Medicine

Drug Discovery

Development

Research

Regional Insights

Loading chart…

The Genomics In Cancer Care market is dominated by North America, which holds the largest share due to advanced healthcare infrastructure, robust R&D investments, and a mature ecosystem driven by leading biopharma players. Europe follows closely, supported by stringent regulatory frameworks and public-private partnerships. The fastest-growing region is the Asia Pacific, fueled by rising cancer incidence, government initiatives (e.g., India’s National Genomic Grid), and expanding collaborations with global entities. Regional forecast data underscores Asia Pacific’s potential, with a CAGR of 12-14% projected through 2030.

In North America, key drivers include high adoption of precision oncology, FDA approvals for genomic therapies, and strong reimbursement policies. Europe benefits from harmonized regulatory standards (e.g., EMA) and investments in AI-driven diagnostics. Asia Pacific is propelled by demographic shifts, rising healthcare spending, and infrastructure modernization. Latin America lags due to fragmented healthcare systems but is gaining traction via low-cost genomic testing partnerships. The Middle East & Africa faces challenges in ecosystem maturity but is seeing incremental growth from increased public funding and awareness campaigns.

Competitive Landscape

The Genomics In Cancer Care competitive landscape is moderately consolidated, with a mix of global leaders and regional players. Major firms such as Illumina, Thermo Fisher Scientific, and Roche dominate through advanced sequencing technologies and regulatory approvals, while mid-sized companies like Agilent and Bio-Rad leverage niche product portfolios and partnerships to capture specialized segments. Pricing remains a critical differentiator, particularly in diagnostic applications, though innovation in liquid biopsy and AI-driven data analytics is reshaping competitive dynamics. Global players prioritize cross-border collaborations to navigate stringent regulatory frameworks, whereas local firms focus on cost-competitive solutions tailored to emerging markets.

Strategies across the sector emphasize M&A, R&D investments, and strategic alliances to expand genomic testing capabilities. Companies like Quest Diagnostics and PerkinElmer are localizing production to mitigate supply chain risks, while Qiagen and Luminex enhance channel strength through OEM agreements. Competitive differentiation hinges on technology leadership (e.g., Pacific Biosciences’ long-read sequencing) and service integration (e.g., Cancer Genetics’ end-to-end solutions). A persistent challenge is rising compliance costs, driven by evolving FDA and EMA guidelines, which disproportionately impact smaller firms lacking economies of scale.

Illumina expands innovation pipeline with next-generation sequencing (NGS) R&D

Thermo Fisher Scientific strengthens OEM tie-ups for diagnostic cartridge systems

Agilent targets premium pricing via high-accuracy PCR instrumentation

Roche advances vertical integration through diagnostic-pharma synergy

Bio-Rad gains cost advantages via local manufacturing in Asia-Pacific hubs

PerkinElmer prioritizes localization of cancer screening programs

Key Genomics In Cancer Care Companies16 items

Illumina

Thermo Fisher scientific

Agilent

Roche

Cancer Genetics

Beckman Coulter

Bio-Rad

Danaher

Sigma Aldrich

Pacific Biosciences

Quest Diagnostics

Luminex

Oxford Gene Technology

PerkinElmer

Qiagen

GE Healthcare

Market Ecosystem

The Genomics In Cancer Care ecosystem spans upstream technology development, midstream data integration, and downstream clinical implementation. Value is generated through precision diagnostics, therapeutic targeting, and longitudinal patient monitoring, with dependencies across sequencing, bioinformatics, and healthcare delivery systems.

Raw material/component suppliers — provide sequencing kits, reagents, and capture probes for genomic analysis

OEMs/Manufacturers — design and produce sequencing platforms, instruments, and automation systems

Technology providers — develop bioinformatics tools for data processing, variant calling, and clinical interpretation

System integrators — deploy end-to-end solutions linking sequencing, data analytics, and electronic health records

Distributors/Channel partners — supply equipment, consumables, and software licenses to laboratories and clinics

Service providers — offer cloud-based genomic analysis, reporting, and interpretation for oncology workflows

End users — include hospitals, academic research centers, and commercial diagnostic laboratories implementing genomic testing

Control points reside in regulatory approvals for diagnostic platforms and clinical validation of bioinformatics algorithms. Dependency risks stem from limited suppliers of proprietary sequencing chemistry and data standardization gaps. End users face high switching costs due to specialized infrastructure, while interoperability between sequencing systems and healthcare IT remains a critical bottleneck.

Recent Industry Insights

The Genomics In Cancer Care industry trends over the past 18 months reflect rapid innovation driven by partnerships, technological advancements, and evolving regulatory frameworks. Major players have intensified collaborations, such as Illumina’s alliance with a leading pharma firm to integrate genomic data into drug development pipelines. Mergers and acquisitions have accelerated, with Roche’s acquisition of a precision oncology startup signaling a strategic push toward end-to-end genomic solutions. Meanwhile, product launches like Guardant Health’s AI-powered liquid biopsy platform and new next-generation sequencing (NGS) tools with 50% faster turnaround times are reshaping diagnostic capabilities.

Regulatory shifts, including the FDA’s expanded approval of companion diagnostics for targeted therapies, underscore a growing emphasis on personalized treatment pathways. Enterprise trends reveal a surge in hospital systems adopting genomic risk assessment tools, driven by declining sequencing costs and improved reimbursement models. Funding activity remains robust, with Series B rounds totaling $250M+ in 2024 for startups leveraging spatial genomics and multi-omics data integration. Looking ahead, the industry is poised to prioritize real-world evidence generation and global equitable access to genomic testing, particularly in emerging markets.

Analyst Overview

The Genomics In Cancer Care market outlook remains highly attractive, driven by advancements in precision oncology, rising demand for personalized therapies, and expanding genomic testing adoption. Technological innovations, including next-generation sequencing (NGS) and AI-driven analytics, are accelerating diagnostic accuracy and treatment optimization, positioning the market for robust growth. However, competitive intensity is escalating, with key players like Illumina, Thermo Fisher Scientific, and emerging biotech firms vying for market share through R&D investments and strategic partnerships.

The long-term outlook is optimistic, supported by favorable reimbursement policies in developed regions and increasing awareness of genomics' role in improving patient outcomes. Nonetheless, the innovation landscape faces challenges in translating research into cost-effective, scalable solutions. Demand–supply balance remains skewed, with testing capacity and skilled personnel lagging behind surging demand. Decision-makers must navigate key risk factors, including regulatory uncertainties, data privacy concerns, and reimbursement barriers, which could hinder market expansion. Strategic focus on interoperability and cost reduction will be critical to sustain growth.

11 items

1. Executive Summary

2. Genomics In Cancer Care Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Genomics In Cancer Care Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Genomics In Cancer Care Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. /> Instruments

6.1.2. Consumables

6.1.3. Services

6.2. Global Genomics In Cancer Care Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. /> Diagnostics

6.2.2. Personalized Medicine

6.2.3. Drug Discovery

6.2.4. Development

6.2.5. Research

6.3. Global Genomics In Cancer Care Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Genomics In Cancer Care Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Genomics In Cancer Care Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Genomics In Cancer Care Market Competition by Key Manufacturers

8.1. Global Genomics In Cancer Care Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Genomics In Cancer Care: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Illumina

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Thermo Fisher scientific

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Agilent

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Roche

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Cancer Genetics

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Beckman Coulter

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Bio-Rad

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Danaher

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Sigma Aldrich

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Pacific Biosciences

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Quest Diagnostics

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Luminex

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Oxford Gene Technology

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. PerkinElmer

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Qiagen

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. GE Healthcare

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Genomics In Cancer Care Market

Figure 4: Global Genomics In Cancer Care Market: Drivers

Figure 5: Global Genomics In Cancer Care Market: Challenges

Figure 6: Global Genomics In Cancer Care Market: Trends

Figure 7: Global Genomics In Cancer Care Market: Opportunity

Figure 8: Global Genomics In Cancer Care Market: Restraint

Figure 9: Global Genomics In Cancer Care Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Genomics In Cancer Care Market Value (USD Million) By Region

Figure 15: Global Genomics In Cancer Care Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Genomics In Cancer Care Market Value (USD Million) By Region

Figure 23: Global Genomics In Cancer Care Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

85 items

Table 1: Market Segmentation Analysis

Table 2: Global Genomics In Cancer Care Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Genomics In Cancer Care Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Genomics In Cancer Care Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Genomics In Cancer Care Market Value (USD Million) By Region

Table 10: Global Genomics In Cancer Care Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Genomics In Cancer Care Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Genomics In Cancer Care Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Genomics In Cancer Care Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Illumina Basic Information And Sales Area

Table 31: Illumina. Products Portfolio

Table 32: Thermo Fisher scientific Basic Information And Sales Area

Table 33: Thermo Fisher scientific. Products Portfolio

Table 34: Agilent Basic Information And Sales Area

Table 35: Agilent. Products Portfolio

Table 36: Roche Basic Information And Sales Area

Table 37: Roche. Products Portfolio

Table 38: Cancer Genetics Basic Information And Sales Area

Table 39: Cancer Genetics. Products Portfolio

Table 40: Beckman Coulter Basic Information And Sales Area

Table 41: Beckman Coulter. Products Portfolio

Table 42: Bio-Rad Basic Information And Sales Area

Table 43: Bio-Rad. Products Portfolio

Table 44: Danaher Basic Information And Sales Area

Table 45: Danaher. Products Portfolio

Table 46: Sigma Aldrich Basic Information And Sales Area

Table 47: Sigma Aldrich. Products Portfolio

Table 48: Pacific Biosciences Basic Information And Sales Area

Table 49: Pacific Biosciences. Products Portfolio

Table 50: Quest Diagnostics Basic Information And Sales Area

Table 51: Quest Diagnostics. Products Portfolio

Table 52: Luminex Basic Information And Sales Area

Table 53: Luminex. Products Portfolio

Table 54: Oxford Gene Technology Basic Information And Sales Area

Table 55: Oxford Gene Technology. Products Portfolio

Table 56: PerkinElmer Basic Information And Sales Area

Table 57: PerkinElmer. Products Portfolio

Table 58: Qiagen Basic Information And Sales Area

Table 59: Qiagen. Products Portfolio

Table 60: GE Healthcare Basic Information And Sales Area

Table 61: GE Healthcare. Products Portfolio

Table 62: Global Market Value (USD Million) (2025-2032) By Type

Table 63: Global Market Share (%) By Type (2032)

Table 64: Global Market Value (USD Million) (2025-2032) By Application

Table 65: Global Market Share (%) By Application (2032)

Table 66: Global Genomics In Cancer Care Market Value (USD Million) By Region

Table 67: Global Genomics In Cancer Care Market Share (%) By Region (2025-2032)

Table 68: North America Market Value (USD Million) (2025-2032) By Country

Table 69: North America Market Value (USD Million) (2025-2032) By Type

Table 70: North America Market Value (USD Million) (2025-2032) By Application

Table 71: Europe Market Value (USD Million) (2025-2032) By Country

Table 72: Europe Market Value (USD Million) (2025-2032) By Type

Table 73: Europe Market Value (USD Million) (2025-2032) By Application

Table 74: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 75: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 76: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 77: South America Market Value (USD Million) (2025-2032) By Country

Table 78: South America Market Value (USD Million) (2025-2032) By Type

Table 79: South America Market Value (USD Million) (2025-2032) By Application

Table 80: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 81: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 82: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 83: Research Programs/Design For This Report

Table 84: Key Data Information From Secondary Sources

Table 85: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Genomics In Cancer Care Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	69.26 billion
Revenue forecast in 2033	120.79 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Illumina; Thermo Fisher scientific; Agilent; Roche; Cancer Genetics; Beckman Coulter; Bio-Rad; Danaher; Sigma Aldrich; Pacific Biosciences; Quest Diagnostics; Luminex; Oxford Gene Technology; PerkinElmer; Qiagen; GE Healthcare
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options